Specifications
| Purity (HPLC) | ≥99% |
|---|---|
| Appearance | Lyophilised white powder |
| Storage | −20 °C, dry, protected from light |
| Pack size | 10 mg |
FOXO4-DRI
$180.00
- Pack10 mg × 10 vials
- Purity≥99%
- Batch
FOXO4-DRI — a D-retro-inverso FOXO4 peptide studied in cellular-senescence research. Supplied as a lyophilised powder in sealed glass vials (10 vials per box). For research use only.
Need more than 10 kits, a different size or a modification? We quote bulk and custom orders within one working day.
All products are sold for laboratory research use only. Not for human or veterinary use, not for diagnostic or therapeutic use.
- HPLC + MS testedEvery batch, with COA
- Lyophilised & sealedStable in transit
- Tracked shippingSame-day dispatch before 15:00
- Discreet packagingPlain outer box
Description
FOXO4-DRI is a D-retro-inverso FOXO4 peptide studied in cellular-senescence research.
Synthesised by solid-phase peptide synthesis and purified by preparative HPLC, with identity confirmed by mass spectrometry. Supplied as a lyophilised powder in sealed glass vials, available in 10 mg.
Each batch is supplied with a certificate of analysis. For research use only — not for human or veterinary use.
Shipping & storage
- Lyophilised peptides ship at ambient temperature in sealed vials with desiccant; they are stable for several weeks in transit.
- On arrival, store at −20 °C away from light. Reconstituted solutions should be aliquoted and kept frozen.
- Orders placed before 15:00 on working days leave the warehouse the same day. Tracking is emailed on dispatch.
- Importing research materials is the buyer’s responsibility; check local regulations before ordering.
Related products
-
Longevity
Glutathione
Price range: $45.00 through $85.00 Select options This product has multiple variants. The options may be chosen on the product page -
Longevity
Epithalon
Price range: $45.00 through $165.00 Select options This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.